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Abstract
CAPN5mutations have been linked to autosomal dominant neovascular inflammatory
vitreoretinopathy (ADNIV), a blinding autoimmune eye disease. Here, we link a new CAPN5
mutation to ADNIV and model the three-dimensional structure of the resulting mutant pro-
tein. In our study, a kindred with inflammatory vitreoretinopathy was evaluated by clinical
eye examinations, DNA sequencing, and protein structural modeling to investigate the dis-
ease-causing mutation. Two daughters of an affected mother demonstrated symptoms of
stage III ADNIV, with posterior uveitis, cystoid macular edema, intraocular fibrosis, retinal
neovascularization, retinal degeneration, and cataract. The women also harbored a novel
guanine to thymine (c.750G>T, p.Lys250Asn) missense mutation in exon 6 of CAPN5, a
gene that encodes a calcium-activated cysteine protease, calpain-5. Modeling based on the
structures of all known calpains revealed the mutation falls within a calcium-sensitive flexi-
ble gating loop that controls access to the catalytic groove. Three-dimensional modeling
placed the new mutation in a region adjacent to two previously identified disease-causing
mutations, all three of which likely disrupt hydrogen bonding within the gating loop, yielding
a CAPN5 with altered enzymatic activity. This is the third case of a CAPN5mutation leading
to inherited uveitis and neovascular vitreoretinopathy, suggesting patients with ADNIV fea-
tures should be tested for CAPN5mutations. Structural modeling of novel variants can be
used to support mechanistic consequences of the disease-causing variants.
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Introduction
Mendelian forms of autoimmune disease are rare. In two large, unrelated kindreds we recently
identified the first mutation shown to cause nonsyndromic uveitis: coding mutations in
CAPN5 caused an inherited uveitis called autosomal dominant neovascular inflammatory
vitreoretinopathy (ADNIV, OMIM #602537) [1]. ADNIV is characterized by progressive, se-
vere intraocular inflammation, photoreceptor degeneration, retinal neovascularization, intra-
ocular fibrosis, and retinal detachment. Otherwise, affected patients have no associated
systemic conditions.
CAPN5 encodes calpain-5, a calcium-activated signaling protease expressed by retinal photo-
receptors [1]. ADNIV-associated mutations in calpain-5 reside in a flexible loop gating the ac-
tive site and are expected to alter enzymatic activity, likely leading to a gain of function [1].
Since the substrate of calpain-5 has not been identified, however, a functional assay for calpain 5
is not currently available. Nevertheless, for calpains in general, excess activity is associated with
retinal and cell degeneration [2–4]. Accordingly, expressing mutant calpain-5 alleles only in the
mouse retina is sufficient to trigger disease [5], while deleting the gene (in the knockout mouse)
does not result in a phenotype [6]. In this study, we identify a new CAPN5mutation in a third
ADNIV family and model the functional effect of this mutation on the protein structure.
Methods
Subjects provided written informed consent under a study approved by the University of
Iowa’s Institutional Review Board, and the study adheres to the tenets set forth in the Declara-
tion of Helsinki. Subjects underwent eye exams that included slit-lamp examination, dilated
retinal biomicroscopy and indirect ophthalmoscopy, optical coherence tomography, and in se-
lected cases, fluorescein angiography (FFA) and electroretinography (ERG).
DNA Sequencing and Analysis
Saliva was collected using Oragene sample collection kits (DNAgenotek, Ontario, Canada),
and DNA was extracted by salt precipitation. PCR primers were designed as previously de-
scribed [1], and products were analyzed with a 3730 DNA sequencer and GeneMapper soft-
ware (Applied Biosystems).
Structural Analysis
Primary and secondary structure protein alignments and trees were created with Geneious Pro
5.4.6 (http://www.geneiouspro.com). A BLAST search for the catalytic core of calpain-5 against
the Protein Database (PDB) returned the structures of the catalytic cores of human calpain-9
with (PDB ID 2P0R; formed catalytic site) and without leupeptin bound (1ZIV; unformed cata-
lytic site) leupeptin bound as the top hits. The sequence identity between target and template
sequences was 42%. Other close matches are the catalytic cores of rat calpain-1 with (1TL9)
and without leupeptin (1QXP), human calpain-1 (2ARY), human calpain-2 (1KFX), rat cal-
pain-2 (1DF0) and human calpain-8 (2NQA). Homology models were generated using MOD-
ELLER 9.14 with the human calpain-9 catalytic cores [7]. The align2d.py python script, which
is part of the MODELLER package, was used to generate an alignment between the human cal-
pain-5 and calpain-9 catalytic cores. The model-single.py python script from the MODELLER
package was then used to generate 10 models, each using the human calpain-9 catalytic cores
(2P0R—apo and 1ZIV—leupeptin bound) as templates. The ten calpain-5 models within each
group superimposed well with most variations in loops far away from the ADNIV mutation
site. The rmsd over about 260 Cα atoms ranged between 0.128–0.232 for the apo template
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models and between 0.078–0.132 for the leupeptin-bound template models. While the apo and
leupeptin-bound template models differed significantly (rmsd of ~ 6.6), this was because of the
domain movements on leupeptin binding. The individual domains IIa and IIb align individual-
ly quite well with rmsds of 0.435 and 0.566 respectively. Since there was very little variation in
the region around our ADNIV mutation site of interest, we picked the top model generated by
MODELLER based off the apo-template as a representative model for figures. PyMOL was
used to generate all structure figures [8].
Results
Phenotypic Ascertainment
The proband (II:1) was a 26 year-old female who began to lose vision at age 23. She was diag-
nosed with noninfectious uveitis with recurrent cystoid macular edema (CME) OU. At the time
of her initial presentation, best-corrected visual acuity measured 20/40 OD and 20/200 OS.
There was no relative afferent pupillary defect, and intraocular pressures were 12 mmHg OU.
Anterior segment examination revealed quiet anterior chambers, 2+ nuclear sclerotic cataracts
OU and 1+ posterior subcapsular cataract OS. Dilated funduscopic exam showed 2+ vitreous
cell OU, 1+ vitreous haze OS with cystoid macular edema OU (Fig 1), but no bone-spicule pig-
mentation or pigment clumping, and the periphery was well vascularized. Despite periocular
corticosteroid injections and triamcinolone acetonide injections, there was recurrent CME and
vitreous inflammation. Over the next six years, she underwent several surgeries in both eyes.
These included fluocinolone acetonide (FA) implantation OU for her uveitis and CME, phacoe-
mulsification and intraocular lens implantation for cataracts, Ahmed tube shunts for steroid-
response glaucoma, and vitrectomies for vitreomacular traction and epiretinal membranes. She
maintained 20/50 OD and 20/100 OS vision for five years until she developed a dense non-
clearing vitreous hemorrhage with a tractional detachment associated with peripheral neovascu-
larization OD. This was repaired with vitrectomy, and because of recurrent vitreous hemorrhage
in the context of recurrent inflammation, she underwent repeat vitrectomy and repeat FA im-
plantation OU. One year later, her visual acuity measured 20/80 OD and 20/50 OS. She now
had diffuse pigmentary spots throughout the peripheral retina. A full-field ERG showed non-
recordable cone and rod responses indicative of severe photoreceptor dysfunction OU.
The proband’s sister (II:2) began to lose vision at age 20, also due to noninfectious uveitis.
She had undergone surgery for vitreomacular traction and epiretinal membranes OU and cata-
racts. Her best-corrected visual acuity measured 20/50 OD and 20/30 OS. There was no relative
afferent pupillary defect, and intraocular pressures were 16 mmHg OD and 18 mmHg OS. An-
terior segment examination revealed subepithelial corneal haze, trace anterior chamber cells,
and posterior chamber intraocular lenses OU. Dilated funduscopic examination showed 1+ vit-
reous cells and a recurrent epiretinal membrane with cystoid macular edema OD (Fig 1). The
patient’s VA was maintained at 20/50 OD and 20/40 OS for five years until a decline to 20/150
OD. She developed a dense fibrotic membrane over the macula and a shallow, inferior, 5 clock-
hour macula-off rhegmatogenous and tractional retinal detachment. The patient underwent a
scleral buckle with cryotherapy OD. Minimal subretinal fluid was present on postoperative day
1. However, on postoperative day 6, she developed an inferior exudative retinal detachment
and her vision was reduced to hand motions. Oral prednisone at 60 mg/day was initiated and
tapered over six weeks; the exudative RD resolved and an improvement in her visual acuity to
20/125 at postoperative month three. Over the next two years, she underwent two vitrectomies
and intravitreal dexamethasone implants for recurrent epiretinal membranes and CME. Never-
theless, her visual acuity declined to 20/400 and the CME recurred. Here left eye showed a
similar decline.
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The sisters’mother was reported to have similar vision loss resulting in blindness. Their fa-
ther and two uncles were not affected (Fig 1). The combination of relentless posterior uveitis,
recurrent CME and epiretinal membranes, peripheral pigmentary degeneration, tractional reti-
nal detachment and retinal neovascularization was consistent with Stage III ADNIV in two
Fig 1. Clinical Imaging. A. The pedigree of a family with clinical features of ADNIV did not show a specific pattern of inheritance. Black symbols represent
clinically affected subjects. Open symbols represent unaffected subjects.B. A color fundus photo of the proband’s (II:1) left macula.C. A fluorescein
angiogram reveals CME (arrow) and temporal window defects.D. Fundus autofluorescence showed a central hyperreflective ring in the macula and
hypofluorescence temporal to the macula (arrows). E, F. Optical coherence tomography (OCT) shows CME greater in the left eye.G. A color fundus photo of
the sister’s (II:2) right macula shows a dense epiretinal membrane (ERM, arrow) over the nerve and macula.H, I. OCT shows an ERM and CMEOU. (ADNIV,
autosomal dominant neovascular inflammatory vitreoretinopathy; CME, cystoid macular edema; OCT, optical coherence tomography; OD, right eye; OS left
eye; OU, both eyes.)
doi:10.1371/journal.pone.0122352.g001
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large pedigrees we previously described. There was no relation to either of these families. The
inheritance pattern was compatible with a highly penetrant, dominant Mendelian disease.
Mutation analysis
Because of the phenotypic similarity to other ADNIV cases, the CAPN5 coding region of the
family members was sequenced. A heterozygous guanine to thymine nucleotide variant, result-
ing in a lysine to asparagine substitution (at genomic position Chr11:77115445, NM_004055.4:
c.750G>T, p.Lys250Asn), was found in both affected subjects but none of the unaffected
(Fig 2). This variant was not present in the dbSNP or 1000 Genome databases. In addition, the
variant allele was not found in the over 13,000 CAPN5 alleles sequenced in the NHLBI Exome
Sequencing Project [9].
Structural Analysis of Calpain-5 ADNIV Mutations
Calpain-5 is a calcium-activated cysteine protease with evolutionarily conserved residues and
domains required for protease activity. The calpain-5 catalytic domain-II is encoded by exon-
6, where we previously identified two disease-causing CAPN5mutations. The newly identified
c.750G>T mutation was also found in exon-6, and mutates Lys250, which is within six amino
acids of the known mutations and one amino acid away from the catalytic histidine residue.
Lys250 is conserved in nearly 100% of vertebrate orthologs. Among the 13 human paralogs,
Lys250 is conserved in seven, and in two other calpains the protein has an identically charged
arginine (Fig 2).
The targets of calpain-5 have not been identified and there is no established method for its
purification and activity measurement. Since there is no functional assay for calpain-5, we ex-
amined how the new ADNIV p.Lys250Asn mutation is structurally related to functional resi-
dues in the catalytic domain-II. Homology modeling to calpain-9 generated a three-
dimensional structure for the calpain-5 catalytic core (Fig 3) [10, 11]. The two previously iden-
tified calpain-5 mutations (p.Arg243Leu, p.Leu244Pro) were modeled as part of a short beta
sheet in a flexible gating loop that undergoes calcium-induced conformation changes during
enzyme activation (Fig 3). (This location is in contrast to the original homology model that
placed these residues in the loop’s alpha helix.) This loop is located on the 5-prime side of the
catalytic groove and controls access to substrates. Interestingly, the new calpain-5 mutation sits
deeper within the catalytic groove but on the same loop. In the primary sequence, the prior two
ADNIV mutations are separated from the newly identified mutation, but when modeled in
three-dimensions, the three mutations lie very near one another (Fig 3).
The gating loop has been found in variable conformations in almost all other calpain crystal
structures or left unmodeled due to poor electron density [10, 12–16], indicating that it is high-
ly flexible (Fig 4). Considering the floppy nature of the loop harboring the ADNIV mutations,
and the lack of conservation in this stretch [10, 12–16], no single model or template completely
captures the different conformations this loop can adopt. However, both the apo and leupeptin
bound structures for calpain-9, which best matches the 9-residue stretch spanning the three
ADNIV mutations in calpain-5, has this segment of the loop locked in an identical conforma-
tion. Therefore, in the context of the catalytic site formation and maintenance, we believe the
homology model based on calpain-9 (Fig 5) provides a better perspective on the effect of all the
ADNIV mutations identified so far [1]. Since calpains do not have a rigid active site, our struc-
tural findings suggest that mutations in this flexible gating loop affect calpain-5 activity. Our
identification of a third disease-causing mutation in this same loop supports the idea that the
loop provides a mechanism for regulating enzymatic activity [14–16].
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Fig 2. TheCAPN5 gene harbors a novel mutation in exon-6. A. Chromatogram of proband showed a heterozygous c.750G>T DNA sequence mutation
(arrow) in exon 6 ofCAPN5. B. Calpain-5 is composed of four domains, and the mutation was located in catalytic domain IIb (green). C. Primary protein
sequence alignment of calpain-5 orthologs shows high evolutionary conservation of the newmutated p.Lys250Asn residue, along with the two prior ADNIV
mutations, p.Arg243Leu and p.Leu244Pro (red arrow/box) in catalytic domain IIb. The two previously identified ADNIV mutations and the newly identified
ADNIV mutation are 2 to 9 amino acids upstream of the histidine catalytic residue (blue box). Amino acid mismatches are color-highlighted.D. Twelve human
calpain family paralogs show the p.Lys250Asn is highly conserved. (Black, 100% similarity; dark grey, 80 to 100% similarity; light grey, 60 to 80% similarity;
white, less than 60% similarity).
doi:10.1371/journal.pone.0122352.g002
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The two known ADNIV mutations, p.Arg243Leu and p.Leu244Pro, are at highly conserved
residues of calpain-5 orthologs and significantly alter the structure of the gating loop by intro-
ducing a hydrophobic leucine in place of a positively charged arginine (p.Arg243Leu) or re-
placing a hydrophobic residue with a rigid proline (p.Leu244Pro). These mutations likely affect
the formation of the alpha helix and beta sheet within this gating loop also observed in other
calpain crystal structures and the homology model of calpain-5 (Fig 4) [1].
Fig 3. Protein structure modeling of calpain-5 and ADNIVmutants. A three dimensional model of the
calpain-5 catalytic domain II was generated using calpain-9 (the closest sequence match) as a template. The
residues of the catalytic triad (yellow sticks) are located in the catalytic groove (outlined in blue) between
domains IIa and IIb. Although the primary sequence (Fig 2) showed the ADNIV Lys250Asn mutation was
several residues away from the two known ADNIV mutations, the three-dimensional model reveals all three
ADNIV mutations (magenta sticks) are adjacent to one another on a flexible gating loop (green) that regulates
enzymatic activity by controlling access to the catalytic groove. This loop samples many conformations,
including a short beta sheet harboring the ADNIV residues as shown here. The mutations alter charged or
hydrophobic residues.
doi:10.1371/journal.pone.0122352.g003
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Our newly identified p.Lys250Asn mutation replaces a longer, positively charged residue
with a shorter, polar residue. This modifies an essential hydrogen bond that appears to be nec-
essary for active-site formation and catalysis. Interestingly, eight of the nine calpain-5 paralogs
with a conserved positively charged residue at the Lys250 position (Lys252 for calpain-9; Fig 2)
also have a conserved negatively charged residue (Asp239 for calpain-5, Glu241 for calpain-9)
on a short alpha-helix with which it forms a salt bridge (Fig 5). This Asp/Glu in turn hydrogen
bonds with the backbone nitrogen of Val235 (Arg237 for calpain-9; Fig 5), suggesting a hydro-
gen bond network locks the loop in place. The hydrogen bonding capability of the shorter,
polar mutant asparagine is quite different from the longer, positively charged lysine it replaces
(Fig 5). The asparagine has the potential to form two hydrogen bonds instead of the single one
that lysine can form; this should affect the interaction with Asp239. Taken together, these
Fig 4. Structure andmodeling of the Calpain-5 gating loop. The flexible gating loop (colored differently in each panel) can be observed in different
conformations across the known structures of the calpain family. The loops shown here are from the crystal structures of calpain-1 (A-E; pdb ids 2ARY,
1ZCM, 1TL9, 1KXR, 1KFX), calpain-2 (F-H; 1U5I, 1MDW, 3DF0), calpain-8 (I; 2NQA), calpain-9 (J, K; 1ZIV, 2P0R) and the homology model of calpain-5 (L).
The loop in its most ordered form tends to have a short alpha helix (C, G, I, J, K, L) and a short beta sheet (D, L). Often the loop is disordered and cannot be
located in the crystal structure due to lack of sufficient electron density (E, F, H). The catalytic residues are shown in yellow and the residues at the site of the
calpain-5 ADNIV mutations are shown in magenta.
doi:10.1371/journal.pone.0122352.g004
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results suggest that amino acid variants in the region adjacent to the catalytic histidine are not
likely to be deleterious, but instead affect the flexible gating loop and catalytic groove, thereby
modifying enzymatic activity.
Discussion
A new, non-synonymous heterozygous mutation in CAPN5 was identified in clinically affected
members of a third family with ADNIV. The clinical phenotype in these patients was similar to
the two kindreds reported previously. This new ADNIV family responded to FA implantation
in the same way as our other ADNIV patients [17, 18]: FA therapy controlled inflammation
and neovascularization, but there was recurrent fibrosis, tractional detachment, and retinal de-
generation. Similar to the patients in this report, we have observed asymmetric disease progres-
sion between eyes of ADNIV twins [19]. Our combined studies on ADNIV and CAPN5
mutations suggest that all patients with an ADNIV phenotype should undergo genetic testing
for CAPN5mutations.
Genes that cause monogenic disorders also harbor polymorphisms that are associated with
more common and sometimes less severe disease. It will be important to determine whether
any CAPN5 polymorphisms are risk factors for patients with the ADNIV-like diseases, such as
uveitis, diabetic retinopathy, retinitis pigmentosa, or proliferative vitreoretinopathy. Genetic
association studies, for example, have identified CAPN5 variants that are risk factors for type II
diabetes, hypertension, high cholesterol, and polycystic ovary syndrome [2, 20–22].
Calpains require careful regulation since they target multiple intracellular proteins and
pathways [23–26]. An unregulated calpain-5 could simultaneously activate different intracellu-
lar pathways. In comparison to caspases that activate apoptotic, noninflammatory cell death
pathways, calpains activate necrotic, inflammatory cell death pathways [27]. This could explain
why CAPN5 retinal degeneration displays a uveitic vitreoretinopathy instead of a noninflam-
matory photoreceptor degeneration typical of retinitis pigmentosa. The finding that FA thera-
py treats some calpain-5 effects supports the concept that calpain-5 activates multiple
downstream pathways. Nevertheless, the target protein substrates for many calpains, including
Fig 5. Hydrogen bonding/salt bridge network at the site of p.Lys250Asn ADNIV mutation. A. In the crystal structure of calpain-9, Lys252 forms a salt
bridge with Glu241, which in turn hydrogen bonds with the backbone nitrogen of Arg237 and locks the flexible gating loop in place.B. The same set of
interactions are observed in the homology model of calpain-5, where Lys250 is well positioned to form a salt bridge with Asp239, which in turn can form a
hydrogen bond with the backbone nitrogen of Val235.C. The p.Lys250Asn (purple) mutation modeled here indicates that Asn250, with altered hydrogen
bonding capability, will interact differently with Asp239 and affect the conformation and flexibility that this catalytically important gating loop adopts. Changes
in the conformation of the gating loop would subsequently alter enzymatic activity.
doi:10.1371/journal.pone.0122352.g005
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calpain-5, have yet to be identified [28]. Unless CAPN5 is directly targeted [29], combination
therapies will be required to address the other pathways that trigger photoreceptor degenera-
tion and intraocular fibrosis.
When visualized in the context of the high-resolution, three-dimensional atomic structures,
seemingly disparate single mutations, which lie separately along the primary protein sequence,
can often be put into perspective. Modeling may be especially illuminating when there is no
bioassay to ascertain the effect of a genetic variant. In the absence of experimentally determined
structures, suitable templates from the growing number of structures in the PDB can yield ho-
mology models that are a good proxy. As we report here, all of the ADNIV mutations identified
so far fall in a flexible gating loop and cluster next to the catalytic site; they seemingly affect the
formation or movement of this loop during ligand binding or catalysis. In three dimensions,
these three mutations cluster together and are part of a backbone or side-chain-mediated hy-
drogen bond network. The model strongly supports the notion that structure of this peptide
loop controls calpain-5 enzymatic activity or specificity. The flexible loops are the most vari-
able region among calpains, and are thought to account for enzymatic differences among cal-
pain isoforms [15, 16, 23]. Minor amino acid substitutions could result in subtle alterations in
specificity and catalytic activity differences between isoforms, as well as in disease-causing mu-
tations. It would be worthwhile to genetically screen for variants in CAPN5 and model them
onto a three-dimensional calpain-5 structure to study the commonality of disease-
causing mechanisms.
Clinical sequencing is producing a wealth of data, but the functional consequences of the re-
sults can often be challenging to interpret. Structural modeling offers insight into underlying
pathobiology but, by itself, modeling has limitations. The most powerful genotype-phenotype
insights can be made in cases such as the present study, when rigorous clinical phenotype ob-
servations coincide with structural analyses.
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